Bimekizumab Significantly Improves Joint, Skin Symptoms in Psoriatic Arthritis
The phase 3 BE OPTIMAL study included 852 adults with active psoriatic arthritis who were biologic disease-modifying antirheumatic drug naïve.
Diagnosis & Disease Information
COVID-19 Pandemic’s Effect on Patients With Psoriatic Disease
The effect of the COVID-29 pandemic on the hospital admissions and treatment adherences of patients with psoriasis are examined.
Durable Improvements Observed With Long-Term Guselkumab in Psoriatic Arthritis Trial
The DISCOVER-2 trial included 739 biologic-naïve adults with active psoriatic arthritis who were treated and followed for approximately 2 years.
First Interchangeable Biosimilar to Humira Gets FDA Approval
The interchangeable biosimilar product may be substituted for the reference product by a pharmacist.
- Loading...
Loading...
Next post in News
Loading... 
Loading...